Epigenetic therapies for cancer
SE Bates - New England Journal of Medicine, 2020 - Mass Medical Soc
Epigenetic Therapies for Cancer Cancer-cell biology is dictated by alterations in epigenetic
regulation of gene expression. Mechanisms underlying these regulators are increasingly …
regulation of gene expression. Mechanisms underlying these regulators are increasingly …
An information-intensive approach to the molecular pharmacology of cancer
…, SH Friend, AJ Fornace Jr, KW Kohn, T Fojo, SE Bates… - Science, 1997 - science.org
Since 1990, the National Cancer Institute (NCI) has screened more than 60,000 compounds
against a panel of 60 human cancer cell lines. The 50-percent growth-inhibitory …
against a panel of 60 human cancer cell lines. The 50-percent growth-inhibitory …
Revisiting the role of ABC transporters in multidrug-resistant cancer
…, KM Pluchino, MD Hall, AT Fojo, SE Bates… - Nature Reviews …, 2018 - nature.com
Most patients who die of cancer have disseminated disease that has become resistant to
multiple therapeutic modalities. Ample evidence suggests that the expression of ATP-binding …
multiple therapeutic modalities. Ample evidence suggests that the expression of ATP-binding …
Multidrug resistance in cancer: role of ATP–dependent transporters
MM Gottesman, T Fojo, SE Bates - Nature reviews cancer, 2002 - nature.com
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the
ability of cancer cells to become simultaneously resistant to different drugs — a trait known as …
ability of cancer cells to become simultaneously resistant to different drugs — a trait known as …
The role of ABC transporters in clinical practice
GD Leonard, T Fojo, SE Bates - The oncologist, 2003 - academic.oup.com
Learning Objectives After completing this course, the reader will be able to: Discuss the
function of ABC transporters. Outline the levels of expression of MDR in tumors. Determine the …
function of ABC transporters. Outline the levels of expression of MDR in tumors. Determine the …
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes
…, M Brangi, L Greenberger, M Dean, T Fojo, SE Bates - Cancer research, 1999 - AACR
Reports of multiple distinct mitoxantrone-resistant sublines without overexpression of P-glycoprotein
or the multidrug-resistance associated protein have raised the possibility of the …
or the multidrug-resistance associated protein have raised the possibility of the …
[HTML][HTML] Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma
…, S Lade, AT Fojo, SE Bates - Journal of clinical …, 2009 - ncbi.nlm.nih.gov
Purpose Romidepsin (depsipeptide or FK228) is a member of a new class of antineoplastic
agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of …
agents active in T-cell lymphoma, the histone deacetylase inhibitors. On the basis of …
The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR (ABCG2)
…, K Miyake, JH Resau, SE Bates - Journal of cell …, 2000 - journals.biologists.com
Mechanisms of drug resistance other than P-glycoprotein are of increasing interest as the
list of newly identified members of the ABC transport family has grown. We sought to …
list of newly identified members of the ABC transport family has grown. We sought to …
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms
…, B Goldspiel, AT Fojo, SP Balcerzak, SE Bates - Clinical Cancer …, 2002 - AACR
Purpose: The primary objectives of this trial were to define the maximum tolerated dose (MTD)
and to characterize the toxicities and pharmacokinetics of depsipeptide (FR901228) given …
and to characterize the toxicities and pharmacokinetics of depsipeptide (FR901228) given …
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
…, M Craig, AT Fojo, JJ Wright, SE Bates - Blood, The Journal …, 2011 - ashpublications.org
Romidepsin (depsipeptide or FK228) is a histone deacetylase inhibitor, one of a new class
of agents active in T-cell lymphoma. A phase 2 trial was conducted in cutaneous (CTCL) and …
of agents active in T-cell lymphoma. A phase 2 trial was conducted in cutaneous (CTCL) and …